Holen Sie sich die Stockscreener-App
6.68
4.64%
-0.32
Schlusskurs vom Vortag:
$7.00
Offen:
$7.05
24-Stunden-Volumen:
295.87K
Relative Volume:
0.57
Marktkapitalisierung:
$189.87M
Einnahmen:
$67.22M
Nettoeinkommen (Verlust:
$-65.78M
KGV:
-2.7988
EPS:
-2.3867
Netto-Cashflow:
$-79.02M
1W Leistung:
-6.12%
1M Leistung:
-7.42%
6M Leistung:
-61.46%
1J Leistung:
-51.98%
1-Tages-Spanne:
$6.64
$7.25
1-Wochen-Bereich:
$6.64
$7.82
52-Wochen-Spanne:
$5.85
$24.17
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Firmenname
Arcturus Therapeutics Holdings Inc
Sektor
Branche
Telefon
(858) 900-2660
Adresse
10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare ARCT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
6.68 | 198.96M | 67.22M | -65.78M | -79.02M | -2.3867 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.43 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.46 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
702.12 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.58 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
283.80 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-23 | Eingeleitet | Roth Capital | Buy |
| 2025-10-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-10-23 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-10-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-09-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-28 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-01-28 | Eingeleitet | BTIG Research | Buy |
| 2024-08-12 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-07-24 | Eingeleitet | William Blair | Outperform |
| 2023-05-11 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-11-14 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-11-10 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2022-11-03 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-11-02 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-08-10 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2022-07-19 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-05-11 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2022-04-21 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-01-31 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-08-12 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2021-08-11 | Herabstufung | Goldman | Neutral → Sell |
| 2021-08-10 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2021-07-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-06-25 | Fortgesetzt | Goldman | Neutral |
| 2021-06-21 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-02-17 | Herabstufung | B. Riley Securities | Neutral → Sell |
| 2021-01-19 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-01-15 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-01-07 | Eingeleitet | Wells Fargo | Overweight |
| 2020-12-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-12-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-12-29 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-12-29 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-23 | Herabstufung | ROTH Capital | Buy → Sell |
| 2020-12-08 | Bestätigt | B. Riley Securities | Buy |
| 2020-12-07 | Bestätigt | B. Riley Securities | Buy |
| 2020-10-26 | Eingeleitet | Barclays | Overweight |
| 2020-10-06 | Eingeleitet | Citigroup | Buy |
| 2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-30 | Fortgesetzt | ROTH Capital | Buy |
| 2020-07-16 | Eingeleitet | Raymond James | Outperform |
| 2020-07-13 | Eingeleitet | B. Riley FBR | Buy |
| 2020-06-09 | Herabstufung | WBB Securities | Buy → Hold |
| 2020-02-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-02-07 | Eingeleitet | Guggenheim | Buy |
| 2020-02-06 | Eingeleitet | Guggenheim | Buy |
| 2019-04-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-09-20 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2018-01-22 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Arcturus Therapeutics Holdings Inc Aktie (ARCT) Neueste Nachrichten
Arcturus Therapeutics Teases 12-Week Phase 2 CF Study After Well-Tolerated Inhaled mRNA Dosing - MarketBeat
Patients and scientists join forces for rare disease progress, Arcturus Therapeutics asserts - Traders Union
Arcturus (ARCT) Q4 2025 Earnings Call Transcript - AOL.com
Stock Report: Can Arcturus Therapeutics Holdings Inc sustain its profitabilityJuly 2025 Fed Impact & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Arcturus Therapeutics: Downgrading to "Hold" As CF Program Shifts Population Focus (ARCT) - Seeking Alpha
Arcturus Therapeutics to attend Leerink Partners 2026 Global Healthcare Conference - Traders Union
Q1 EPS Forecast for Arcturus Therapeutics Reduced by Analyst - MarketBeat
Demystifying Arcturus Therapeutics: Insights From 4 Analyst Reviews - Benzinga
Citigroup Lowers Price Target for Arcturus Therapeutics (ARCT) t - GuruFocus
Citigroup Issues Pessimistic Forecast for Arcturus Therapeutics (NASDAQ:ARCT) Stock Price - MarketBeat
Arcturus Therapeutics to Attend Upcoming Investor Conference - PharmiWeb.com
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2025 Earnings Call Transcript - Insider Monkey
ARK Investment Management LLC Boosts Position in Arcturus Therapeutics Holdings Inc. $ARCT - MarketBeat
Piper Sandler Maintains Overweight on Arcturus Therapeutics (ARCT) March 2026 - Meyka
Gossamer Bio, Seralutinib Misses Tight Statistical Mark But Shows Heart In High-Risk Lung Disease Study - AOL.com
Arcturus Therapeutics Holdings ARCT Q4 Revenue Slide To US$7.2 Million Tests Growth Narrative - simplywall.st
Arcturus Therapeutics Holdings Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Citigroup Issues Positive Forecast for Arcturus Therapeutics (NASDAQ:ARCT) Stock Price - MarketBeat
Citigroup Raises Price Target for Arcturus Therapeutics (ARCT) t - GuruFocus
Piper Sandler Lowers Price Target for Arcturus Therapeutics (ARC - GuruFocus
New nasal vaccine protects lungs for months against viruses, bacteria, and allergens - AOL.com
Piper Sandler Cuts Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $25.00 - MarketBeat
Arcturus Therapeutics reports financial results and pipeline progress - Traders Union
Arcturus Therapeutics Holdings Inc earnings missed by $5.31, revenue fell short of estimates - Investing.com Australia
Arcturus Therapeutics Holdings Inc (ARCT) Q4 2025 Earnings Call - GuruFocus
Arcturus Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Arcturus Q4 2025 misses expectations, stock drops By Investing.com - Investing.com South Africa
Arcturus Therapeutics Q4 Earnings Call Highlights - MarketBeat
Arcturus Therapeutics falls 5% on weak quarterly revenue - Investing.com
ARCTURUS THERAPEUTICS ($ARCT) Releases Q4 2025 Earnings - Quiver Quantitative
Arcturus (ARCT) Faces Shortfall in Q4 Revenue, Focuses on New Th - GuruFocus
Arcturus Therapeutics Holdings Inc earnings missed by $5.31, revenue fell short of estimates By Investing.com - Investing.com Canada
Arcturus Therapeutics (NASDAQ:ARCT) Releases Earnings Results, Misses Estimates By $0.11 EPS - MarketBeat
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates - Prime Publishers, Inc.
Arcturus Therapeutics Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Arcturus Therapeutics falls 5% on weak quarterly revenue By Investing.com - Investing.com Canada
Arcturus Therapeutics 10-K: Revenue $82.0M; EPS not reported - TradingView
KOSTAIVE setback and mRNA pipeline progress at Arcturus (NASDAQ: ARCT) - Stock Titan
Arcturus Therapeutics (ARCT) trims 2025 loss and extends cash runway into Q2 2028 - Stock Titan
Arcturus Therapeutics Q4 Earnings Assessment - Benzinga
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress - Yahoo Finance
Earnings Preview: Arcturus Therapeutics - Benzinga
Precision Trading with Arcturus Therapeutics Holdings Inc. (ARCT) Risk Zones - Stock Traders Daily
What To Expect From Arcturus Therapeutics Holdings Inc (ARCT) Q4 2025 Earnings - GuruFocus
Momentum Shift: How liquid is Arcturus Therapeutics Holdings Inc stockJuly 2025 Weekly Recap & Real-Time Buy Signal Notifications - baoquankhu1.vn
Bethany Children's Health Center unveils immersive experience plans - AOL.com
Arcturus Therapeutics Holdings Inc expected to post a loss of 71 cents a shareEarnings Preview - TradingView
Arcturus Therapeutics (ARCT) Stock Analysis: Exploring a 304% Potential Upside Amidst Clinical Pipeline Advances - DirectorsTalk Interviews
Arcturus Therapeutics (ARCT) Expected to Post Earnings on Tuesday - MarketBeat
Arcturus Therapeutics Holdings (ARCT) Stock Analysis: A Potential 346% Upside with Innovative mRNA Therapies - DirectorsTalk Interviews
Technical Reactions to ARCT Trends in Macro Strategies - Stock Traders Daily
Finanzdaten der Arcturus Therapeutics Holdings Inc-Aktie (ARCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):